Report : Asia Pacific Genotyping Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product and Services (Instruments, Reagents and Kits, Bioinformatics, and Genotyping Services), Technology [Microarrays, Capillary Electrophoresis, Sequencing, Polymerase Chain Reaction (PCR), Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry, and Others], Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Animal Genetics, Agricultural Biotechnology, and Others), and End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostic and Research Laboratories, Academic Institutes, and Others)
At 22.0% CAGR, the Asia Pacific Genotyping Market is speculated to be worth US$ 17,668.09 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific genotyping market was valued at US$ 5,365.20 million in 2022 and is expected to reach US$ 17,668.09 million by 2028, registering an annual growth rate of 22.0% from 2022 to 2028. The wide applications of genotyping and use of genotyping in drug development for genetic are the critical factors attributed to the market expansion.
The genotyping platform has several potential applications, such as pharmacogenomics, diagnostic research, personalized medicine, and agricultural biotechnology. In addition, this technique is suitable for a variety of forensic, plant breeding, and environmental testing requirements. Pharmaceutical companies increasingly turn to genetic data to help them choose medication targets and build precision medicine strategies. Most major pharmaceutical firms regularly collect pharmacogenomic (PGx) studies from clinical trial participants. Pharmaceutical businesses are benefiting from advances in genomics, such as the availability of substantial genetic databases connected to patient health information, the rising use of polygenic risk scores, and the direct sequencing of clinical trial participants. The Industry Pharmacogenomics Working Group (I-PWG) is an association of pharmaceutical companies actively involved in pharmacogenomics research. The I-PWG comprises 26 member companies that undertake hundreds of clinical trials annually, many of which include DNA collection as part of the protocol. This I-PWG perspective aims to provide an overview of the present opportunities that pharmaceutical companies in clinical pharmacogenomics are facing. In 2017, an unpublished survey of I-PWG members indicated that 79% of members had used NGS technologies for internal PGx research (in at least one study), and more than a third of members had used these technologies extensively. Companies reported using NGS for whole-genome and whole-exome sequencing of clinical trial participants in 53% and 71% of cases, respectively. While NGS technologies were most frequently reported for oncology research, firms also stated that NGS technologies were being used for PGx studies in various non-oncology therapeutic areas, such as cardiology, neuroscience, immunology, and rare disorders. The use of NGS on clinical trial samples allows for a more comprehensive genomic examination of trial participants and a broader study for PGx analysis that encompasses both common and rare genetic variations. Further, the study of polymorphic differences in drug response and disease susceptibility, detection of drug/xenobiotic effects at the genomic level, and genotype/phenotype relationships are all part of pharmacogenomics. There are now several unique ways to detect SNPs. Modifications of traditional techniques such as PCR, mass spectrometry, and sequencing, as well as more innovative technologies such as fluorescence resonance energy transfer and microarrays, are among the new methodologies. In recent years, the prices of high-throughput sequencing and genotyping have dropped dramatically, and businesses are now regularly doing complete genetic profiling of clinical trial participants. Large databases integrating patient health and genetic data have become valuable drug development resources. These databases may be used to find new targets and characterize current ones more thoroughly. SNPs are now widely used in genetic analysis and breeding. Large-scale genotyping at the whole genome level is becoming increasingly crucial for understanding the genetic structure of complex traits. Genotyping-by-sequencing (GBS) is a new way to find and genotype SNPs in crop genomes and populations using NGS methods. GBS has been created and deployed in sequencing multiplexed samples that integrate molecular marker discovery with genotyping to further widen NGS applications to giant crop genomes such as maize and wheat. The GBS method involves restriction enzyme digestion of genomic DNA, barcode adapter ligation, PCR amplification, and sequencing of the amplified DNA pool on a single lane of flow cells. To analyze and understand GBS datasets, bioinformatic workflows are required. High-throughput SNPs detected by genotyping by sequencing (GBS) are widely used in genetic diversity analysis, genome-wide association studies (GWAS), QTL mapping, and genome prediction (GP) in many plant species. NGS technologies have led to remarkable advances in whole-genome sequencing, which provides ultra-throughput sequences to revolutionize plant genotyping and breeding. NGS technology has transformed modern biology with high throughput and low cost. Sequencing by synthesis (SBS) and Multiplexing have greatly improved the efficiency of the sequence. Further, large genomic datasets connected to patient health and medical data are increasingly being used by pharmaceutical companies through partnerships, collaborations, or acquisitions.
On the contrary, high cost of equipment and shortage of skilled professionals required for genotyping process hurdles the growth of Asia Pacific genotyping market.
The Asia Pacific genotyping market, based on product and services, has been segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held 37.0% market share in 2022, amassing US$ 1,985.22 million. It is projected to garner US$ 6,700.30 million by 2028 to expand at 22.5% CAGR during 2022–2028.
The Asia Pacific genotyping market, based on technology is segmented into Microarrays, Capillary Electrophoresis, Sequencing, Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-ToF) Mass Spectrometry, Polymerase Chain Reaction (PCR), and others. The Polymerase Chain Reaction (PCR) segment held 28.8% market share in 2022, amassing US$ 1,545.96 million. It is projected to garner US$ 5,277.32 million by 2028 to expand at 22.7% CAGR during 2022–2028.
The Asia Pacific genotyping market, based on application is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and others. The diagnostics and personalized medicine segment held 32.5% market share in 2022, amassing US$ 1,742.99 million. It is projected to garner US$ 5,789.08 million by 2028 to expand at 22.1% CAGR during 2022–2028.
The Asia Pacific genotyping market, based on end user is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and others. The diagnostic and research laboratories segment held 47.1% market share in 2022, amassing US$ 2,526.73 million. It is projected to garner US$ 8,526.37 million by 2028 to expand at 22.5% CAGR during 2022–2028.
Based on country, the Asia Pacific genotyping market is categorized into Japan, China, India, Australia, South Korea, and the rest of Asia Pacific. Our regional analysis states that Japan captured 34.4% market share in 2022. It was assessed at US$ 1,847.92 million in 2022 and is likely to hit US$ 6,183.83 million by 2028, exhibiting a CAGR of 22.3% during the forecast period.
Key players dominating the Asia Pacific genotyping market are BioTek Instruments, Inc.; Eurofins Genomics; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; Integrated DNA Technologies, Inc.; MERCK KGaA; QIAGEN; Thermo Fisher Scientific Inc; TrimGen Corporation; and XCELRIS GENOMICS among others.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org